Abstract
Plasmapheresis has considerably improved the management of patients affected by myasthenia gravis (MG), particularly in case of severe acute worsening with bulbar impairment. Controlled trials against placebo are not available in this field, but evidences emerged from open-label studies are considered a strong confirmation of the clinical efficacy of plasmapheresis in MG. More recently, the techniques of selective apheresis based on the properties of protein A and sheep anti-human IgG have been introduced into clinical practice, allowing chronic apheresis in treatment-resistant MG patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
